Navigation Links
Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
Date:12/7/2007

been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Enzyme promotes fat formation
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
9. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
10. Senior Research Analyst Richard Evans Joins AVOS Life Sciences
11. Schering-Plough Announces Pricing of Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... inventions licensed to biotechnology firms has revealed early ... these roadblocks, the researchers suggest that better communication ... could lead to faster commercialization down the road. ... made in university laboratories and licensed to biotechnology ... which have a high failure rate. But a ...
(Date:8/20/2014)... succeeded in measuring vibrational motion of a single molecule ... vibration of a single molecule differs from the behaviour ... performed at the University of California, Irvine, where post-doctoral ... as a visiting fellow under professor Vartkess A. Apkarian, ... was lead by Professor Eric O. Potma. The results ...
(Date:8/20/2014)... High performance computing (HPC) will be ... climate and Earth system model to address the ... Eight national laboratories, including Lawrence Livermore , ... Atmospheric Research, four academic institutions and one private-sector ... laboratories include Argonne, Brookhaven, Lawrence Berkeley, Los Alamos, ...
(Date:8/20/2014)... 2014  PAREXEL International Corporation (NASDAQ: PRXL ... the Baird Healthcare Conference in New York.  Ingo ... will be making a presentation on PAREXEL and discussing ... 3, 2014. A live webcast of the ... PAREXEL,s website at www.PAREXEL.com in the Upcoming ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2
... Inc., a,privately-held, development-stage pharmaceutical company dedicated to treating,diseases ... defenses, today,announced that the National Institutes of Health ... excess of $850,000. , ... to advance the development of safe and,effective medical ...
... InSightec Ltd.,announced today that cancer patients suffering pain ... have a new online resource for information about,their ... bone metastases, as well as detailed information about ... the U.S., Canada and,Israel to evaluate whether treatment ...
... Who Can Benefit from Vectibix(R) , ... Amgen (Nasdaq: AMGN ) today announced they ... gene as a predictive biomarker in patients with ... receptor (EGFr) antibody Vectibix(R) (panitumumab) with the U.S. Food ...
Cached Biology Technology:Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury 2Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury 3MyCancerPain.org Launched as Resource for Patients with Painful Bone Metastases 2MyCancerPain.org Launched as Resource for Patients with Painful Bone Metastases 3Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 2Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 3Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 4Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 5Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 6Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 7Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 8
(Date:8/20/2014)... -- Bay Area Lyme Foundation, which aims to make ... applauds new research published in an upcoming issue of ... Diseases . The findings show that ticks that ... the year, making the threat of Lyme disease year-round. ... of Public Health (CDPH) Vector-borne Disease Section and University ...
(Date:8/20/2014)... that acral melanomas the rare type of skin cancer ... distinct from other more common types of skin cancer, according ... Pigment Cell & Melanoma Research . , Acral melanoma ... the feet, nail-beds and other hairless parts of the skin. ... by UV damage from the sun. , The team, from ...
(Date:8/20/2014)... and salty aroma of sunscreen and seawater signals a ... reporting that the idyllic beach vacation comes with an ... and into the sea, they can become toxic to ... main course for many other marine animals. Their study ... Technology . , Antonio Tovar-Sanchez and David Snchez-Quiles point ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... improve its system for ensuring the safety of its ... Academy of Sciences say. Despite having 40% of the ... independent regulatory agency and sufficient staff to keep pace ... article in ACS,s journal Environmental Science & Technology. ...
... The obscure technology used in heated automobile seats, gadgets that ... devices is undergoing a renaissance and could well emerge as ... play other key roles in addressing some of society,s most ... the technology termed thermoelectrics in the current issue ...
... Elser, Argentina,s soaring, glacier-laden peaks, ancient cultures, and criollo ... draw: access to the "last unpolluted aquatic ecosystems on ... Elser and colleague Esteban Balseiro of the Universidad Nacional ... alpine lakes close to San Carlos de Barliloche in ...
Cached Biology News:Fulbright scholar takes ecological theory to Andean heights 2Fulbright scholar takes ecological theory to Andean heights 3
... exciting new chapter to a ... Agilents 7890A GC gives you ... your lab to the next ... performance, including advanced separation capabilities, ...
... often call for critical, but time-consuming ... refines siRNA transfection protocols resulting in ... can be used to efficiently transfect ... without increased cytotoxicity. From start ...
... CaspaTag™ Pan-Caspase In Situ Assay Kit is ... caspases in cells undergoing apoptosis. The kit ... use in diagnostic or therapeutic procedures. CHEMICON®s ... a novel approach to detect active caspases. ...
... INTERFERin is a new-generation siRNA transfection ... efficiency at 1 nM siRNA in a ... with excellent cell viability. Using low siRNA ... effects observed when transfecting siRNA at higher ...
Biology Products: